Randox Laboratories introduces Prostate-specific Antigen (PSA). This allows testing for indications of prostate cancer and other prostate conditions such as prostatitis and benign prostatic hyperplasia.

15 May 2023

Produced by both normal and malignant prostate cells, PSA functions to liquify semen in the seminal coagulum allowing sperm cells to move freely and to dissolve the cervical mucus permitting the sperm cells migration to the uterus.

Levels of PSA are low in healthy men but elevate in the presence of prostate cancer and other mentioned conditions.

PSA screening is recommended for men over 40 years old that would be considered high risk: Black men, men with germline variants of BRCA1 or BRCA2 and/or men with a family history of prostate cancer.

For those not considered to be high-risk, screening is still recommended between the ages of 55-70.

Features & Benefits:

  • Manufactured using human serum, ensuring a matrix like patient sample.
  • This control has been optimised for use with Roche systems, but it is suitable for use across a variety of other platforms.
  • Liquid Frozen format for convenience and reduced handling errors. It has an impressive open vial stability of thirty days at 2 degrees Celsius – eight degrees Celsius minimising waste. There is also one year of shelf life from the date of manufacture.
  • The control has been optimised for use with Roche systems, but it is also suitable for a variety of other platforms.    


Privacy Policy
We have updated our privacy policy. In the latest update it explains what cookies are and how we use them on our site. To learn more about cookies and their benefits, please view our privacy policy. Please be aware that parts of this site will not function correctly if you disable cookies. By continuing to use this site, you consent to our use of cookies in accordance with our privacy policy unless you have disabled them.